NASDAQ:DEPO - Depomed Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$7.24 -0.11 (-1.50 %)
(As of 06/21/2018 04:00 PM ET)
Previous Close$7.35
Today's Range$7.18 - $7.41
52-Week Range$4.31 - $11.27
Volume1.79 million shs
Average Volume1.26 million shs
Market Capitalization$459.10 million
P/E Ratio-5.75
Dividend YieldN/A
Beta1.2
Depomed logoDepomed, Inc., a specialty pharmaceutical company, engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the United States. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults; and Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults. The company also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, it is involved in the clinical development of Cebranopadol for the treatment of chronic nociceptive and neuropathic pain. Depomed, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc.; and a license agreement with Janssen Pharmaceuticals, Inc. based on its proprietary Acuform gastroretentive drug delivery technology. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is headquartered in Newark, California.

Receive DEPO News and Ratings via Email

Sign-up to receive the latest news and ratings for DEPO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:DEPO
CUSIP24990810
Phone510-744-8000

Debt

Debt-to-Equity Ratio2.55
Current Ratio0.75
Quick Ratio0.73

Price-To-Earnings

Trailing P/E Ratio-5.75
Forward P/E Ratio-15.08
P/E GrowthN/A

Sales & Book Value

Annual Sales$380.72 million
Price / Sales1.21
Cash Flow$0.8389 per share
Price / Cash8.63
Book Value$2.69 per share
Price / Book2.69

Profitability

EPS (Most Recent Fiscal Year)($1.26)
Net Income$-102,490,000.00
Net Margins-10.02%
Return on Equity-15.74%
Return on Assets-2.95%

Miscellaneous

Employees434
Outstanding Shares63,590,000

Depomed (NASDAQ:DEPO) Frequently Asked Questions

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed Inc (NASDAQ:DEPO) posted its earnings results on Thursday, May, 10th. The specialty pharmaceutical company reported $0.28 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.69. The specialty pharmaceutical company earned $128.40 million during the quarter, compared to analyst estimates of $65.77 million. Depomed had a negative return on equity of 15.74% and a negative net margin of 10.02%. The company's quarterly revenue was up 41.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.07 EPS. View Depomed's Earnings History.

When is Depomed's next earnings date?

Depomed is scheduled to release their next quarterly earnings announcement on Monday, August, 6th 2018. View Earnings Estimates for Depomed.

What price target have analysts set for DEPO?

7 brokers have issued twelve-month price targets for Depomed's shares. Their forecasts range from $5.00 to $10.00. On average, they expect Depomed's stock price to reach $8.00 in the next twelve months. View Analyst Ratings for Depomed.

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:
  • Mr. Arthur Joseph Higgins, CEO, Pres & Director (Age 62)
  • Mr. August J. Moretti, CFO & Sr. VP (Age 67)
  • Mr. Matthew M. Gosling, Sr. VP, Gen. Counsel & Sec. (Age 47)
  • Mr. Sean P. McKercher, Sr. VP of Operations & Bus. (Age 61)
  • Dr. Stan Bukofzer, Sr. VP and Chief Medical & Scientific Officer (Age 62)

Has Depomed been receiving favorable news coverage?

Media stories about DEPO stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Depomed earned a media sentiment score of 0.24 on Accern's scale. They also gave news articles about the specialty pharmaceutical company an impact score of 47.95 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Depomed's major shareholders?

Depomed's stock is owned by a number of of institutional and retail investors. Top institutional investors include STARBOARD VALUE LP (6.10%), Dimensional Fund Advisors LP (5.21%), STARBOARD VALUE LP (4.30%), Prudential Financial Inc. (1.87%), Millennium Management LLC (1.68%) and State of Wisconsin Investment Board (1.52%). Company insiders that own Depomed stock include Arthur J Higgins, August J Moretti, Matthew M Gosling and Thadd M Vargas. View Institutional Ownership Trends for Depomed.

Which major investors are selling Depomed stock?

DEPO stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, State of Wisconsin Investment Board, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Deltec Asset Management LLC, GSA Capital Partners LLP, Schwab Charles Investment Management Inc., Systematic Financial Management LP and Cubist Systematic Strategies LLC. View Insider Buying and Selling for Depomed.

Which major investors are buying Depomed stock?

DEPO stock was acquired by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Opaleye Management Inc., Dimensional Fund Advisors LP, Massachusetts Financial Services Co. MA, Redwood Investment Management LLC, Hsbc Holdings PLC, Engineers Gate Manager LP and Mackay Shields LLC. View Insider Buying and Selling for Depomed.

How do I buy shares of Depomed?

Shares of DEPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of DEPO stock can currently be purchased for approximately $7.24.

How big of a company is Depomed?

Depomed has a market capitalization of $459.10 million and generates $380.72 million in revenue each year. The specialty pharmaceutical company earns $-102,490,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Depomed employs 434 workers across the globe.

How can I contact Depomed?

Depomed's mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company can be reached via phone at 510-744-8000 or via email at [email protected]


MarketBeat Community Rating for Depomed (DEPO)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  421 (Vote Outperform)
Underperform Votes:  313 (Vote Underperform)
Total Votes:  734
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe DEPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DEPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.